Babraham Institute Enterprise Limited (BIE) is the wholly-owned trading arm of the Babraham Institute. The Babraham Institute undertakes innovative life-sciences research to discover the molecular mechanisms that underlie normal cellular processes and functions, with the aim of improving lifelong wellbeing and healthy ageing. It is based on the Babraham Research Campus near Cambridge, which is also home to early-stage biomedical companies.. . The Institute aims to maximise the impact of its research through knowledge exchange and commercialisation, and its scientists work with other organisations to translate that research into action for social and economic benefit. BIE supports the delivery of the commercialisation of the Babraham Institute's science. As part of this role, it manages, develops and commercialises the Babraham Institute's intellectual property portfolio. It also facilitates collaborations between the Institute and industry, and arranges access to the Institute's expertise and scientific facilities and services.
Babraham Research Campus Ltd is the company that manages and develops the Babraham Research Campus, supporting and promoting the regional and UK bioscience ecosystem. It has responsibility for the administration and commercial development of the site for the benefit of all the tenants including the Babraham Institute. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
Watch our Member Showcase video here https://bit.ly/3A1MjXZ
BBI Cambridge is the UK operating company of the Biotechnology Business Institute based in Barcelona.
Findacure is a UK charity that is building the rare disease community to drive research and develop treatments. We work to: 1) Empower patient groups to build their patient community, develop as a charity and drive research; 2) Promote collaboration between rare disease stakeholders to facilitate treatment development for all.
Watch our member showcase video here https://bit.ly/3rhRi2D
Main activities are: fundraising for early stage life science companies, helping companies become investment ready; advice on obtaining R&D grants; interim and financial management for early stage companies; and contributing to board decisions as non-executive director. Experience includes raising equity for eight life science companies and obtaining R&D grants for 16 others. Also 12 years managing small companies and a number of non-executive director posts.
The Company's strong balance sheet makes Proximagen one of the best capitalised biotechnology companies in the small and mid cap European biotech sector.. . Proximagen is developing a broad pipeline of drug candidate programmes and has plans for substantial future growth through a strategy of acquisition and consolidation in its preferred therapeutic area of the central nervous system.. . Proximagen's Corporate Objectives:. . * Expanding our pipeline within CNS through in-house discovery, acquisition, in-licencing and partnering, thus building quality and critical mass in research and development.. * Offer a rewarding corporate culture to motivate and retain our employees.. * Retention of strong downstream participation in all commercialised programs. . . Proximagen is committed to the best interests of patients, the medical profession, our employees and our communities, and to seeking significant returns for our shareholders, based on the continuous pursuit of scientific and operational excellence.
Bicycle has developed a proprietary bicyclic peptide technology that enables the discovery of a new class of drug candidates with antibody-like selectivity and specificity. The company is well financed by a group of top-tier VCs and is applying the technology to drug discovery projects in several therapeutic areas. The company also plans to also enter selected research collaborations to make the platform available to pharma partners.
Bidwells is the leading property consultancy in the Oxford-Cambridge Arc, advising on over half of all science and technology space in the region. We manage over £5.2bn in property assets for national and international investors, and serve as a gateway to highly attractive markets for science and technology corporations and investors. We help businesses to find or develop new office and laboratory space, project manage fit-outs and refurbishments, and we provide building and planning consultancy, relocation and acquisition advice, and lease consultancy.